Kasper CK - Search Results

1

Continuous infusion of porcine factor VIII in patients with haemophilia A and high-responding inhibitors: stability and clinical experience.

O'Gorman P, Dimichele DM, Kasper CK, Mannucci PM, Santagostini E, Hay CR. O'Gorman P, et al. Among authors: kasper ck. Haemophilia. 2001 Nov;7(6):537-43. doi: 10.1046/j.1365-2516.2001.00558.x. Haemophilia. 2001. PMID: 11851750

2

Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey.

Hay CR, Lozier JN, Lee CA, Laffan M, Tradati F, Santagostino E, Ciavarella N, Schiavoni M, Fukui H, Yoshioka A, Teitel J, Mannucci PM, Kasper CK. Hay CR, et al. Among authors: kasper ck. Thromb Haemost. 1996 Jan;75(1):25-9. Thromb Haemost. 1996. PMID: 8713775

3

Continuous infusion of porcine factor VIII: stability, microbiological safety and clinical experience.

DiMichele DM, Gorman PO, Kasper CK, Mannucci PM, Santagostino E, Hay CR. DiMichele DM, et al. Among authors: kasper ck. Haemophilia. 2002 Jan;8 Suppl 1:9-12; discussion 28-32. doi: 10.1046/j.1365-2516.2002.00129.x. Haemophilia. 2002. PMID: 11882076

4

Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.

Lozier JN, Santagostino E, Kasper CK, Teitel JM, Hay CR. Lozier JN, et al. Among authors: kasper ck. Semin Hematol. 1993 Apr;30(2 Suppl 1):10-21. Semin Hematol. 1993. PMID: 8480192 Review.

5

Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.

Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E. Hay CR, et al. Among authors: kasper ck. Thromb Haemost. 1998 Apr;79(4):762-6. Thromb Haemost. 1998. PMID: 9569189

6

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.

Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, Laurian Y, Kasper CK, Mannucci PM. Lusher JM, et al. Among authors: kasper ck. Haemophilia. 1998 Nov;4(6):790-8. doi: 10.1046/j.1365-2516.1998.00209.x. Haemophilia. 1998. PMID: 10028299 Clinical Trial.

7

Panel discussion on the treatment of patients with factor VIII inhibitors.

Lusher JM, Eyster ME, Hilgartner MW, Kasper CK, Mannucci PM, Nilsson IM, Penner JA, Roberts HR. Lusher JM, et al. Among authors: kasper ck. Prog Clin Biol Res. 1984;150:323-35. Prog Clin Biol Res. 1984. PMID: 6431437 No abstract available.

8

Hemophilia: state of the art of hematologic care 1988.

Kasper CK, Graham JB, Kernoff PB, Larrieu MJ, Rickard KA, Mannucci PM. Kasper CK, et al. Vox Sang. 1989;56(3):141-4. doi: 10.1111/j.1423-0410.1989.tb02016.x. Vox Sang. 1989. PMID: 2658317 Review.

9

Kinetics of factor IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-purity factor IX replacement.

Liebman HA, Rosenwald-Zuckerman T, Retzios A, Yasmin S, Kasper CK. Liebman HA, et al. Among authors: kasper ck. Haemophilia. 1999 May;5(3):174-80. doi: 10.1046/j.1365-2516.1999.00305.x. Haemophilia. 1999. PMID: 10444284 Clinical Trial.

10

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.

Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D. Seremetis S, et al. Among authors: kasper ck. Haemophilia. 1999 Jan;5(1):9-16. doi: 10.1046/j.1365-2516.1999.00191.x. Haemophilia. 1999. PMID: 10215942 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

140 results

Search Page